so, we want kisqali. longer is possible and proven with kisqali when taken with a nonsteroidal aromatase inhibitor in premenopausal women with hr+, her2- metastatic breast cancer. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor alone. kisqali can cause lung problems or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash or are plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. it's our time. for more time

so, we want kisqali. living longer is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or

so, we want kisqali.er is possible and proven with kisqali when taken with a nonsteroidal aromatase inhibitor in premenopausal women with hr+, her2- metastatic breast cancer. kisqali is a pill that's significantly more effective dayinasogression her2- metastatic breast cancer. oida aromatase inbitor e. kisqali is a pill that's significantly more effective kisqali can cause lung problems or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash or are plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use w

so, we want kisqali. living longer is possible and proven with kisqali when taken with a nonsteroidal aromatase inhibitor in premenopausal women with hr+, her2- metastatic breast cancer. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor alone. kisqali can cause lung problems or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. ask your doctor abou

so, we want kisqali.possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avo

so, we want kisqali. living longer is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or

so, we want kisqali.ssible and proven with kisqali when taken with a nonsteroidal aromatase inhibitor in premenopausal women with hr+, her2- metastatic breast cancer. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor alone. kisqali can cause lung problems or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. ask your doctor about living longer with

so, we want kisqali.longer is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfe

so, we want kisqali.th kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during t

so, we want kisqali.hen taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. ki

so, we want kisqali.en taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kis

so, we want kisqali.n taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisq

so, we want kisqali.when taken with a nonsteroidal aromatase inhibitor in premenopausal women with hr+, her2- metastatic breast cancer. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor alone. kisqali can cause lung problems or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash or are plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. it's our time. for more time. we asked for kisqali. ask your doctor abou

so, we want kisqali. or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for

so, we want kisqali.r2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. it's our time. for more time.

so, we want kisqali.ken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali

so, we want kisqali. inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. it's our

so, we want kisqali.nsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with

so, we want kisqali.ving longer is possible and proven with kisqali when taken with a nonsteroidal aromatase inhibitor in premenopausal women with hr+, her2- metastatic breast cancer. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor alone. kisqali can cause lung problems or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash or are plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. it's our time. for more

so, we want kisqali. with a nonsteroidal aromatase inhibitor in premenopausal women with hr+, her2- metastatic breast cancer. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor alone. kisqali can cause lung problems or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash or are plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. it's our time. for more time. we asked for kisqali. ask your doctor about living l